Recent studies demonstrate that biomarkers of bone metabolism, particularly the OPG/TRAIL ratio, are powerful predictors of cardiovascular disease and mortality in patients with type 2 diabetes and chronic kidney disease, offering improved risk stratification beyond traditional clinical factors.